Drug Profile
Research programme: thrombin inhibitors - Fulcrum Pharmaceuticals
Alternative Names: Thrombin inhibitors research programme - Fulcrum PharmaceuticalsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fulcrum Pharmaceuticals
- Class Small molecules
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
- 21 Feb 2005 Preclinical trials in Thrombosis in USA (PO)